SAGE Therapeutics Inc (NASDAQ:SAGE) Given Average Recommendation of “Buy” by Brokerages

Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) have received a consensus recommendation of “Buy” from the sixteen research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $199.80.

Several analysts have commented on the company. William Blair reissued a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. JPMorgan Chase & Co. reissued a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. Oppenheimer dropped their price objective on SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. BidaskClub lowered SAGE Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 27th. Finally, ValuEngine lowered SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 2nd.

SAGE traded up $1.03 during trading on Friday, hitting $137.00. The company’s stock had a trading volume of 1,473 shares, compared to its average volume of 376,639. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a twelve month low of $79.88 and a twelve month high of $193.56. The business’s fifty day simple moving average is $156.42 and its 200 day simple moving average is $167.36. The firm has a market capitalization of $7.21 billion, a price-to-earnings ratio of -17.01 and a beta of 2.54.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) EPS for the quarter, beating the consensus estimate of ($3.32) by $0.04. The business had revenue of $0.87 million during the quarter, compared to analyst estimates of $0.27 million. During the same period in the previous year, the business posted ($0.36) earnings per share. The firm’s revenue for the quarter was down 99.0% on a year-over-year basis. As a group, equities research analysts forecast that SAGE Therapeutics will post -13.47 earnings per share for the current fiscal year.

In other news, Director James M. Frates sold 8,000 shares of SAGE Therapeutics stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $160.58, for a total value of $1,284,640.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 4.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SAGE. Dimensional Fund Advisors LP boosted its stake in SAGE Therapeutics by 40.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 109,054 shares of the biopharmaceutical company’s stock worth $10,441,000 after buying an additional 31,571 shares during the last quarter. Comerica Bank acquired a new position in SAGE Therapeutics during the first quarter worth $278,000. Great West Life Assurance Co. Can boosted its stake in SAGE Therapeutics by 10.1% during the first quarter. Great West Life Assurance Co. Can now owns 6,251 shares of the biopharmaceutical company’s stock worth $991,000 after buying an additional 574 shares during the last quarter. BlackRock Inc. boosted its stake in SAGE Therapeutics by 6.5% during the first quarter. BlackRock Inc. now owns 2,673,467 shares of the biopharmaceutical company’s stock worth $425,216,000 after buying an additional 162,976 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in SAGE Therapeutics by 19.4% during the first quarter. Wells Fargo & Company MN now owns 371,305 shares of the biopharmaceutical company’s stock worth $59,057,000 after buying an additional 60,204 shares during the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Recommended Story: Understanding Market Liquidity

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit